Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOPACS: Evolocumab in Acute Coronary Syndromes
NCT03287609Phase 3Completed
- Sponsor
- Insel Gruppe
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in acute coronary syndrome (ACS), sponsored by Insel Gruppe. Started Jan 2018; status: completed.
02
Drugs
evolocumab
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03287609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287609.